PFE vs. AZN.L
Compare and contrast key facts about Pfizer Inc. (PFE) and AstraZeneca plc (AZN.L).
Performance
PFE vs. AZN.L - Performance Comparison
Loading graphics...
PFE vs. AZN.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PFE Pfizer Inc. | 16.58% | 0.65% | -2.22% | -41.26% | -10.41% | 66.70% | 3.07% | -6.91% | 24.82% | 15.90% |
AZN.L AstraZeneca plc | 8.83% | 44.74% | -0.76% | 1.56% | 18.18% | 20.68% | 2.05% | 39.35% | 12.56% | 32.60% |
Different Trading Currencies
PFE is traded in USD, while AZN.L is traded in GBp. To make them comparable, the AZN.L values have been converted to USD using the latest available exchange rates.
Fundamentals
PFE:
$162.34B
AZN.L:
£234.79B
PFE:
$1.36
AZN.L:
£6.64
PFE:
20.95
AZN.L:
22.61
PFE:
0.38
AZN.L:
0.03
PFE:
2.60
AZN.L:
3.94
PFE:
1.74
AZN.L:
4.82
PFE:
$62.58B
AZN.L:
£59.50B
PFE:
$44.01B
AZN.L:
£46.54B
PFE:
$15.10B
AZN.L:
£20.04B
Returns By Period
In the year-to-date period, PFE achieves a 16.58% return, which is significantly higher than AZN.L's 8.83% return. Over the past 10 years, PFE has underperformed AZN.L with an annualized return of 4.49%, while AZN.L has yielded a comparatively higher 16.90% annualized return.
PFE
- 1D
- 1.67%
- 1M
- 4.73%
- YTD
- 16.58%
- 6M
- 8.56%
- 1Y
- 24.79%
- 3Y*
- -5.70%
- 5Y*
- 0.19%
- 10Y*
- 4.49%
AZN.L
- 1D
- 2.93%
- 1M
- -2.25%
- YTD
- 8.83%
- 6M
- 20.49%
- 1Y
- 38.44%
- 3Y*
- 15.29%
- 5Y*
- 17.49%
- 10Y*
- 16.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PFE vs. AZN.L — Risk / Return Rank
PFE
AZN.L
PFE vs. AZN.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and AstraZeneca plc (AZN.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PFE | AZN.L | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.94 | 1.34 | -0.41 |
Sortino ratioReturn per unit of downside risk | 1.46 | 1.99 | -0.52 |
Omega ratioGain probability vs. loss probability | 1.18 | 1.27 | -0.09 |
Calmar ratioReturn relative to maximum drawdown | 1.66 | 2.32 | -0.66 |
Martin ratioReturn relative to average drawdown | 3.73 | 7.48 | -3.75 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| PFE | AZN.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.94 | 1.34 | -0.41 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.01 | 0.70 | -0.69 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.19 | 0.67 | -0.48 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.27 | 0.44 | -0.17 |
Correlation
The correlation between PFE and AZN.L is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
PFE vs. AZN.L - Dividend Comparison
PFE's dividend yield for the trailing twelve months is around 6.02%, more than AZN.L's 1.57% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PFE Pfizer Inc. | 6.02% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
AZN.L AstraZeneca plc | 1.57% | 1.77% | 2.23% | 2.21% | 1.98% | 2.33% | 2.95% | 2.87% | 3.44% | 4.28% | 4.50% | 3.95% |
Drawdowns
PFE vs. AZN.L - Drawdown Comparison
The maximum PFE drawdown since its inception was -58.96%, which is greater than AZN.L's maximum drawdown of -43.96%. Use the drawdown chart below to compare losses from any high point for PFE and AZN.L.
Loading graphics...
Drawdown Indicators
| PFE | AZN.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.96% | -49.99% | -8.97% |
Max Drawdown (1Y)Largest decline over 1 year | -12.59% | -15.14% | +2.55% |
Max Drawdown (5Y)Largest decline over 5 years | -58.96% | -26.75% | -32.21% |
Max Drawdown (10Y)Largest decline over 10 years | -58.96% | -26.75% | -32.21% |
Current DrawdownCurrent decline from peak | -41.79% | -3.35% | -38.44% |
Average DrawdownAverage peak-to-trough decline | -17.33% | -11.71% | -5.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.58% | 5.94% | -0.36% |
Volatility
PFE vs. AZN.L - Volatility Comparison
The current volatility for Pfizer Inc. (PFE) is 6.30%, while AstraZeneca plc (AZN.L) has a volatility of 7.06%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than AZN.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| PFE | AZN.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.30% | 7.06% | -0.76% |
Volatility (6M)Calculated over the trailing 6-month period | 17.39% | 15.43% | +1.96% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.78% | 28.48% | -1.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.47% | 24.94% | +0.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.90% | 25.03% | -1.13% |
Financials
PFE vs. AZN.L - Financials Comparison
This section allows you to compare key financial metrics between Pfizer Inc. and AstraZeneca plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PFE vs. AZN.L - Profitability Comparison
PFE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a gross profit of 12.29B and revenue of 17.56B. Therefore, the gross margin over that period was 70.0%.
AZN.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AstraZeneca plc reported a gross profit of 12.39B and revenue of 15.50B. Therefore, the gross margin over that period was 79.9%.
PFE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported an operating income of 3.69B and revenue of 17.56B, resulting in an operating margin of 21.0%.
AZN.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AstraZeneca plc reported an operating income of 2.98B and revenue of 15.50B, resulting in an operating margin of 19.2%.
PFE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a net income of -1.65B and revenue of 17.56B, resulting in a net margin of -9.4%.
AZN.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AstraZeneca plc reported a net income of 2.33B and revenue of 15.50B, resulting in a net margin of 15.0%.